Renewed coverage of Jordan Peterson on May 1, 2026 has put akathisia back in the spotlight, and advocates are using the moment to press for stronger drug warnings and faster diagnosis. MISSD said the attention should push doctors and regulators to do more to identify the condition before patients are harmed.
Akathisia is a medication-induced neuropsychiatric disorder that can bring severe inner agitation, an inability to sit still, panic, insomnia and intense psychological distress. In severe cases, it has been associated with self-harm, violence and suicide. MISSD says it can occur with or without visible movement and is often mistaken for an underlying psychiatric illness rather than an adverse drug effect.
Jordan Peterson’s symptoms were described publicly by his daughter, Mikhaila Peterson, drawing new attention to a condition many patients say they were never warned about. MISSD says akathisia has been linked to hundreds of medications, including dopamine-blocking drugs, certain anti-nausea medicines, some anti-infective and antimalarial drugs, antidepressants, antipsychotics and medications used for acne or hair loss, as well as other central nervous system drugs.
The push for disclosure is also showing up in a Change.org petition launched by akathisia survivor Stacey Haza, who is calling for black box warnings that explicitly name and describe the disorder. Black box warnings are the U.S. Food and Drug Administration’s most serious safety warnings, and the campaign argues they should be used to make akathisia harder to miss. Wendy Dolin said akathisia is not clearly disclosed in current drug labeling, which contributes to delayed recognition and misdiagnosis, and added that clear warnings and accurate recognition are essential to preventing harm.
Haza said, “I just remember that things weren’t right. I felt like I was crawling out of my skin. I was afraid of literally everything.” She also said that in the prescribed harm community, one of the most common refrains is, “I wish someone had told me—I wish I had known.” A site, prescribed-harm.com, has also been created for people to share experiences related to akathisia and iatrogenic harm.
The renewed attention around Peterson has already pushed the condition beyond specialist circles and into wider public view across major U.S., Canadian and U.K. outlets. For advocates, the next test is whether that visibility leads to changes in labeling, more clinical awareness and earlier recognition for patients whose distress is being mistaken for something else.
